Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation by Aizhen Liu et al.
January 2016 | Volume 6 | Article 161
Review
published: 29 January 2016
doi: 10.3389/fonc.2016.00016
Frontiers in Oncology | www.frontiersin.org
Edited by: 




New York University School of 
Medicine, USA 
Kamalakannan Palanichamy, 
The Ohio State University Medical 
Center, USA
*Correspondence:
Xuan Zong  
lulianwei666666@163.com
Specialty section: 
This article was submitted to 
Neuro-Oncology, 






Liu A, Hou C, Chen H, Zong X and 
Zong P (2016) Genetics and 
Epigenetics of Glioblastoma: 
Applications and Overall Incidence of 
IDH1 Mutation. 
Front. Oncol. 6:16. 
doi: 10.3389/fonc.2016.00016
Genetics and epigenetics of 
Glioblastoma: Applications and 
Overall incidence of iDH1 Mutation
Aizhen Liu1 , Chunfeng Hou2 , Hongfang Chen1 , Xuan Zong3* and Peijun Zong1
1 Department of Oncology, Yidu Central Hospital, Jinan, China, 2 Department of Oncology Nursing, Yidu Central Hospital, 
Jinan, China, 3 Department of Oncology, Shandong University School of Medicine, Jinan, China
Glioblastoma is the most fatal brain cancer found in humans. Patients suffering from 
glioblastoma have a dismal prognosis, with a median survival of 15 months. The tumor 
may develop rapidly de novo in older patients or through progression from anaplastic 
astrocytomas in younger patients if glioblastoma is primary or secondary, respectively. 
During the past decade, significant advances have been made in the understanding of 
processes leading to glioblastoma, and several important genetic defects that appear 
to be important for the development and progression of this tumor have been identified. 
Particularly, the discovery of recurrent mutations in the isocitrate dehydrogenase 1 
(IDH1) gene has shed new light on the molecular landscape in glioblastoma. Indeed, 
emerging research on the consequences of mutant IDH1 protein expression suggests 
that its neomorphic enzymatic activity catalyzing the production of the oncometabolite 
2-hydroxyglutarate influences a range of cellular programs that affect the epigenome 
and contribute to glioblastoma development. One of the exciting observations is the 
presence of IDH1 mutation in the vast majority of secondary glioblastoma, while it is 
almost absent in primary glioblastoma. Growing data indicate that this particular muta-
tion has clinical and prognostic importance and will become a critical early distinction in 
diagnosis of glioblastoma.
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iNTRODUCTiON
Glioblastoma is the most common brain malignancy and one of the most aggressive cancers found 
in humans. It is divided into primary and secondary types. Both are histologically identical, so clini-
cal features are used to distinguish them. Primary glioblastoma manifests rapidly de novo without 
recognizable precursor lesions, and is by far the more common, accounting for 80% of cases. It 
predominates in elderly patients and is characterized by rapid progression and short survival time. 
Secondary glioblastoma evolves from lower-grade gliomas, such as grade II diffuse astrocytoma or 
grade II anaplastic astrocytoma, and is typically seen in younger patients. It can be diagnosed with 
clinical or histological evidence (1). Infiltrating glioblastomas are incurable with current treatment 
modalities that include surgery, radiation, and chemotherapy. For newly diagnosed patients, the 
standard treatment is total removal, if possible, followed by the combination of chemotherapy and 
radiotherapy (2, 3). However, despite this maximum treatment, the prognosis of patients remains 
dismal with a median survival of 15 months only (2). When compared with other malignancies, there 
TABLe 1 | Genes commonly mutated in glioblastoma.
Gene 
symbol




EGFR Epidermal growth 
factor receptor
Regulator of cell signaling 






Regulator of cell signaling 






NF1 Neurofibromin 1 Regulator of cell signaling 





Regulator of cell signaling 




kinase regulatory 1 
Regulator of cell signaling 
involved in cell proliferation 
and survival
7–8
PTEN Phosphatase and 
tensin homolog
Regulator of cell signaling 
involved in cell proliferation 
and survival
24–37
PTPRD Protein tyrosine 
phosphatase receptor 
type D
Regulator of cell signaling 
involved in cell proliferation 
and survival
0–6
RB1 Retinoblastoma 1 Regulator of cell cycle 8–13
TP53 Tumor protein p53 Apoptosis 31–38
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have only been small improvements in the prognosis of glioblas-
toma patients over recent decades. Nevertheless, understanding 
of the molecular pathogenesis of glioblastoma has greatly 
increased and is beginning to match that of other types of cancers. 
Several important genetic alterations have been known for some 
time, but new technologies have allowed much deep genetic and 
epigenetic analysis of large numbers of glioblastoma samples, 
leading to a number of novel discoveries. One of the most exciting 
and clinically relevant observations was the discovery that a high 
percentage of secondary glioblastomas and a very small percent-
age of primary glioblastoma harbor mutations in the isocitrate 
dehydrogenase 1 (IDH1) gene. This stunning and unexpected 
discovery that holds clear clinical implications has led to new 
insights into glioblastoma biology. Indeed, IDH1 mutation results 
in gain of function to catalyze the production of hydroxyglutarate 
(2-HG) (4), a possible oncometabolite that is thought to influence 
a range of cellular programs involved in epigenetic control and 
various processes leading to tumor development. Here, we review 
translational applications of this mutation as well as its incidence 
in glioblastoma and other cancers. In addition, we highlight 
importance of epigenetic changes that may need to be considered 
in future diagnostics and therapy for glioblastoma. Initially, the 
review presents a brief overview on mutations commonly found 
in glioblastoma, and prunes the consequences of IDH1 mutation 
on glioblastoma biology to better understand the potential role of 
this particular mutation in the development of this tumor.
COMMON MUTATiONS iN 
GLiOBLASTOMA
Although glioblastoma-specific mutations are seen, mutations 
in common cancer genes, such as TP53 and PTEN, are very 
frequent in glioblastomas, but are not of prognostic importance 
(Table 1) (5, 6). EGFR point mutations have also been identified 
in glioblastoma. The EGFRvIII mutant lacks 267 amino acids in 
the extracellular part, resulting in a constitutively activated recep-
tor that no longer requires its ligand EGF to signal downstream 
(5). Although mutations in certain cancer genes, such as BRAF 
and the RAS genes, have rarely been observed in glioblastoma, 
inactivating mutations and deletions have been identified in 
their inhibitory tumor-suppressor gene NF1 (5). Mutations in 
PIK3CA and PIK3R1 genes, coding, respectively, for the PI3K 
catalytic subunit p110α and regulatory subunit P85α, have also 
been described (5, 6).
An interesting gene found to contain mutations in glioblas-
toma is IDH1, which encodes IDH1 and is involved in energy 
metabolism. This gene shows differential expression between 
primary and secondary glioblastoma, while PTEN loss, EGFR 
amplification, and loss of heterozygosity (LOH) of chromosome 
10 are associated with primary glioblastoma, and ATRX muta-
tion, loss of p53, and LOH of chromosome 19 are common in 
secondary glioblastoma. The IDH1 mutation predicts secondary 
glioblastoma better than these other mutations predict their 
respective glioblastoma subtype. Indeed, IDH1 mutations have 
been predominantly identified in secondary glioblastoma and 
low-grade gliomas, with mutations in more than 70% of cases 
(5, 6). They are found only sporadically in primary glioblastoma 
(5, 6). Because patients with IDH1-mutated primary glioblastoma 
are generally younger and have longer median survival and wild-
type EGFR, which are characteristics of secondary glioblastoma, 
it is hypothesized that these are in fact secondary glioblastomas 
for which no histological evidence of evolution from a less malig-
nant glioma is found. Therefore, IDH1 mutation could be used to 
differentiate primary from secondary glioblastoma.
BiOLOGiCAL CONSeQUeNCeS OF iDH1 
MUTATiON
Isocitrate dehydrogenase 1 is a metabolic enzyme that converts 
isocitrate into α-ketoglutarate (α-KG) via oxidative decarboxyla-
tion using NADP+ as an electron acceptor, and producing NADPH 
(7). While NADPH is thought to be important for limiting cellular 
oxidative damage and for lipid biosynthesis, α-KG is considered 
as an essential intermediate in the Kreb’s cycle. Under hypoxia 
conditions, IDH1 catalyzes the inverse reaction, converting α-KG 
to isocitrate which can in turn be converted to acetyl-CoA for 
lipid metabolism and many biochemical reactions.
Since 2008, with the discovery of recurrent mutations in the 
IDH1 coding gene by the Vogelstein group analyzing the DNA 
sequence of the glioblastoma genome (6), substantial progress has 
been made to understand how such genetic modification leads 
IDH1 to play a role in the tumorigenesis. The major finding was 
the discovery that the IDH1 mutation is a gain-of-function muta-
tion, conferring neomorphic activity to IDH1. Initially, a pivotal 
study profiling IDH1 wild-type and mutant glioblastoma cells 
FiGURe 1 | Potential mechanisms implicated in tumor formation induced by iDH1 mutation. A number of potential mechanisms have been proposed to 
explain how R-2-HG produced by mutant IDH1 enzyme promotes tumor formation. Epigenetic modification, via inhibition of α-KG-dependent dioxygenases leading 
to DNA and histone hypermethylation, has been at the forefront of research efforts. Specifically, the inhibition of tet methylcytosine dioxygenase 2 (TET2) leads to 
increased DNA hypermethylation and the inhibition of histone demethylases leads to increased histone tail methylation. Additional mechanisms include inhibition of 
several groups of prolyl hydroxylases, leading to hypoxia-induced factor (HIF) activation and alterations in collagen formation.
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with liquid chromatography–mass spectrometry has reported 
high levels of the metabolite 2-HG in mutant cells (4). Then, it 
has been demonstrated that mutant IDH1 catalyzes the reduction 
of α-KG to the R-enantiomer of the metabolite 2-HG (R-2-HG) 
(8). Thus, rather than catalyze the NADP+-dependent produc-
tion of α-KG, mutant IDH1 catalyzes the NADPH-dependent 
reduction of α-KG to produce only the R-enantiomer of 2-HG, 
indicating a gain of neomorphic function. Specifically, authors 
have demonstrated that the mutation reduces the affinity of the 
IDH1 active site for isocitrate while concomitantly increasing it 
for NADPH and α-KG (8). Reduced affinity for isocitrate occurs 
as a result of alterations to a binding site residue that forms 
hydrogen bonds between the alpha and beta groups of isocitrate 
(8). Consequently, the conversion of α-KG is favorized, but rather 
than isocitrate, the mutant enzyme converts α-KG into R-2-HG, 
an oncometabolite that promotes tumorigenesis through inhibi-
tion of α-KG-dependent (Figure 1).
iNCiDeNCe OF IDH1 MUTATiON iN 
GLiOBLASTOMA AND OTHeR CANCeRS
Extensive genomic profiling has revealed that about 90% of IDH1 
mutations involve exon 4 at codon 132, replacing arginine with 
histidine (R132H). Of the remaining 10% of IDH1 mutations, 
4.7% are due to arginine being replaced with cysteine (R132C), 
2.1% with glycine (R132G), 1.7% with serine (R132S), 0.8% with 
leucine (R132L), and 0.3% with glutamine (R132Q) (9).
Following the first observation of recurrent IDH1 mutation in 
glioblastoma, several groups have begun to clarify the frequency 
and distribution of IDH1 mutation across all brain tumors, 
including gliomas and other subtypes. Data summarized from 
many studies show that only approximately 5.6% of primary 
glioblastoma are IDH1 mutant, while more than 76% of second-
ary glioblastomas carry the IDH1 mutation. The reported rates 
of IDH1 mutation in lower-grade gliomas are comparable with 
those of secondary glioblastoma (Table 2) (10).
Other brain tumors harboring IDH1 mutations with moderate 
frequency include gangliogliomas, giant cell glioblastomas, and 
primitive neuroectodermal tumors, although only small numbers 
of these tumors have been studied (11).
Isocitrate dehydrogenase mutations are also present in some 
tumors originating in cells outside of the central nervous system. 
Indeed, about 7.7% of acute myeloid leukemia (AML) possessed 
the IDH1 mutation (12), but prevalence rates vary between 15 
and 33% if IDH2 are also considered (13). Approximately 50% of 
d-2-hydroxyglutaric aciduria (d-2-HGA), a rare inherited neuro-
metabolic disorder, has also been found to display IDH1 mutations 
(14), as well as 10% of intrahepatic cholangiocarcinomas (15), 5% 
of myelodysplastic syndrome (MDS), 8.8% of myeloproliferative 
neoplasms (MPN), and fewer than 10% of secondary AML (14). 
TABLe 2 | Frequency of iDH1 mutation in various tumors.
Tumor types iDH1 mutation frequency (%)
Astrocytoma pilocytic (WHO Grade I) 0.01
Diffuse glioma (WHO Grade II) 76
Astrocytoma anaplastic (WHO Grade III) 62.2
Primary glioblastoma (WHO Grade IV) 5.6
Secondary glioblastoma (WHO Grade IV) 76.4
Oligodendroglioma
WHO Grade II 78.8
WHO Grade III 67.5
Oligoastrocytoma
WHO Grade II 79.8
WHO Grade III 69.7
CNS, central nervous system; WHO, World Health Organisation; AML, acute myeloid 
leukemia; d-2-HGA, d-2-hydroxyglutaric aciduria; MDS, myelodysplastic syndrome; 
MPN, myeloproliferative neoplasms.
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In their investigation, Amary and colleagues found that nearly 
60% of central and periosteal cartilaginous tumors displayed 
DH1mutations (16). The same group has also identified IDH1 
mutation to occur in patients with Ollier disease and Maffucci 
syndrome (17). The majority of patients exhibited the R132C 
IDH1 mutation, in contrast to most secondary glioblastoma, 
which harbor the R132H mutation.
TRANSLATiONAL APPLiCATiONS OF 
MUTANT iDH1
In a relatively short time after the discovery of IDH1 mutation in 
glioblastoma, a tremendous amount of work has been performed 
on the clinical relevance of this mutation regarding particularly 
its applications in the diagnosis, prognosis, and treatment of 
patients suffering from glioblastoma.
Diagnostic Applications
The determination of IDH1 mutation status is highly relevant 
for the diagnosis of primary brain tumors, and strongly supports 
the differential diagnosis between an anaplastic glioma and a 
glioblastoma.
Traditionally, IDH1 mutation status was detected through 
classic Sanger sequencing and polymerase chain reaction (PCR). 
Although this has the clear advantage of being able to detect non-
R132H mutation, it is time consuming and requires there to be 
at least 20% mutant allele frequency within the tissue specimen 
for reliable detection (18). Pyrosequencing is an alternative that 
allows for rapid high-throughput analysis of IDH1 mutation, and 
has demonstrated an advantage over classic Sanger sequencing 
in that it can detect mutated allele frequencies down to 5% (19). 
Derived cleaved amplified polymorphic sequence analysis is 
another alternative to DNA sequencing that uses mismatched 
primers for specific mutations, which, following PCR amplifica-
tion will create differing restriction endonuclease sites depend-
ent on the presence of the mutation (20). The advantage of this 
technique is that it uses supplies commonly found in most labo-
ratories, obviating expensive sequencing equipment. However, 
unlike sequencing, the method is limited in that it can only detect 
mutations being queried. Other PCR-based techniques include 
coamplification at lower temperature (COLD) PCR with high-
resolution melting (HRM) and real-time PCR, and post-PCR 
fluorescent melting curve analysis (FMCA). Through COLD 
PCR combined with HRM, Boisselier and colleagues were able to 
detect mutant allele concentrations of 0.25% in a span of only 3 h 
(21). However, because the technique requires the new mutation 
to have a melting temperature (Tm) that is lower than IDH1 wild 
type, it theoretically may not be able to detect R132G mutation. 
Regarding real-time PCR with post-PCR FMCA, this technique 
was shown to be more sensitive than Sanger sequencing with 
detection rate of as little as 10% mutant DNA and a processing 
time of 80 min.
Other technologies currently in use to detect mutations in the 
IDH1 gene include SNaPshot (22) and Oncomap (23), both of 
which can be used with paraffin-embedded tissue, using base pair 
extension that results in an allele-specific probe that is read out by 
either fluorescence detection (SNaPshot) or mass spectrometry 
(Oncomap). In addition to these approaches, Boisselier and 
colleagues demonstrated evidence of principle in detection of 
IDH1 mutations from the plasma of patients with mutant glioma 
(24). Although the potential application for monitoring disease 
non-invasively is compelling, the sensitivity attained using this 
assay was 60%. Further work on the nature of circulating tumor 
material will be necessary to determine whether it will be possible 
to monitor the IDH1 mutation status in the peripheral blood of 
all patients with mutant gliomas.
Recently, a new technique called amplification-refractory 
mutation system (ARMS) has been developed (25) to identify 
R140Q mutations in IDH2 and such novel methods can be of 
great help in detecting IDH1 mutations. Recently, a novel strategy 
of PCR clamping was employed for qualitative detection of seven 
different mutations in IDH1 and five mutations in IDH2 in a 
single PCR assay (26).
A monoclonal antibody specific for the IDH-R132H mutation 
(mIDH1R132H), developed by Capper’s group, recognizes the 
mutant protein with a high degree of sensitivity and specific-
ity (27). Using this antibody, 90% of IDH1 mutation can be 
detected on paraffin sections, and it is recommended to test 
the remaining 10% by sequencing. Nevertheless, proponents of 
immunohistochemistry-based antibody staining argue that the 
use of mIDH1R132H antibody to identify IDH1 mutation may 
even be superior to direct sequencing because there are reported 
cases in which this antibody detects mutations missed by direct 
sequencing (28).
Beyond determination of IDH1 mutation status, the histo-
pathological utility of the mIDH1R132H antibody has extended to 
additional clinical scenarios such as the discrimination between 
diffuse astrocytoma and reactive astrocytosis when combined 
with a panel of key molecular feature (29). Indeed, seeing that 
IDH1 mutations are specific to gliomas, this antibody can be 
used to help differentiate between diffuse gliomas and areas of 
reactive gliosis. Accordingly, the detection of positive cells by 
IDH1-R132H immounohistochemistry allows a clear and safe 
separation between low-grade glioma and reactive gliosis, and 
clearly supports the diagnosis of a diffusely infiltrating glioma 
as well as the differential diagnosis between an anaplastic glioma 
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and a glioblastoma. This approach allows narrowing down the 
possible diagnosis to the group of diffusely infiltrating of WHO 
grade II and III and secondary glioblastoma and to a certain 
extent to primary glioblastoma. IDH1-R132H immounohisto-
chemistry has also been shown to be effective in separating out 
oligodendrogliomas from several other similar entities, such as 
central neurocytomas, tanycytic ependymomas, and pilocytic 
astrocytomas (27).
Another area of investigation has focused on the detection of 
the 2-HG metabolite rather than on the specific sequence of the 
IDH1 gene or protein product. In theory, sensitive and specific 
detection of 2-HG is sequence independent in that 2-HG should 
be present regardless of the type of mutation in IDH1 or IDH2. 
High levels of 2-HG have been detected in ex vivo tissue samples 
by using two approaches. In the first approach, combination 
gas or liquid chromatography/mass spectrometry was used to 
identify 2-HG in frozen or paraffin-embedded glioma tissue. 
However, these extraction-based approaches do not preserve the 
integrity of the sampled tissue. In the second approach, proton 
high-resolution magic angle spinning (HRMAS) MRS is used to 
determine the metabolic profiles in ex vivo tissue. This technique 
does not require alteration of tissue samples, and identified 2-HG 
in ex vivo specimens with high sensitivity and specificity. Unlike 
the case with AML, wherein 2-HG can be detected in the blood 
of patients with IDH-mutant AML (30), its presence in peripheral 
blood is similar between patients with IDH1-mutant and wild-
type tumors (31).
Detection of 2-HG by MRS represents a completed non-
invasive method with which to determine the presence of IDH 
mutations in gliomas, irrespective of the sequence of the muta-
tion or the mutation maps to IDH1 or IDH2. Importantly, this 
approach represents the only example in human cancer in which 
a genomic feature can be identified specifically by using imaging-
based metabolic profiling. Prior work completed by MRS-based 
approach has demonstrated that IDH-mutant tumors display 
characteristic imaging findings. The IDH1-mutant tumors dis-
play reduced contrast enhancement, less surrounding edema, 
cystic components, and often found in the frontal lobe compared 
with IDH-wild-type tumors (32). Because it is recognized that the 
spectrum of 2-HG has some overlap with other commonly found 
metabolites, such as glutamate and glutamine, the methodology 
for obtaining and analyzing in  vivo MRS is critical. One study 
to demonstrate 2-HG detection in glioma by MRS used the 
acquisition of a point-resolved spectroscopy (PRESS) sequence 
(33). There was good concordance between sequence-based 
mutation status and 2-HG detection, although several false 
positives and false negatives were reported. Additional studies in 
which spectral-editing analysis (34) or 2D-correlation MRS with 
spectral editing (35) were used demonstrated that IDH mutation 
status can be identified non-invasively by MRS techniques with a 
high levels of sensitivity and specificity.
Prognostic implications
Extensive research has been performed to determine the prog-
nostic value of IDH1 mutations, and a better prognosis has been 
generally reported in glioblastoma patients carrying an IDH1 
mutation. Studies have shown that IDH1 mutation convey an 
improved prognosis with respect to both overall survival and 
progression-free survival for the rare glioblastoma patients 
who express this mutation. Indeed, since the publication of the 
first report on improved survival in glioblastoma patients with 
mutation by Parsons and colleagues, indicating 45.6  months 
overall survival in IDH1-mutant versus 13.2  months overall 
survival in IDH1 wild type (6), numerous groups have been able 
to replicate similar findings (36–41). Besides improved overall 
survival, Sanson et al. (37) were able to demonstrate improved 
progressive-free survival (PFS) as well in their set of patients 
with glioblastoma, with 55  months PFS in patients with IDH1 
mutation versus 8.8 months PFS in those without this mutation. 
The analysis was extended to anaplastic (WHO grade III) tumors 
because many groups were readily able to show an improved 
overall survival in grade III tumors that harbored the IDH1 muta-
tion compared with those that did not in both univariate (36) 
and multivariate analyses (37, 40). With anaplastic astrocytomas, 
patients harboring IDH1 mutation had an overall survival of 
65  months compared to 20  months for patients without IDH1 
mutation (38). The survival benefit also extended to grade II glio-
mas, showing a median overall survival of 12.6 years in patients 
with IDH1 mutation versus 5.5 years in patients devoid of this 
mutation. In a prospective analysis, Wick and colleagues found 
that grade III astrocytomas that possessed the IDH1 mutation 
were associated with greater PFS regardless of the treatment (42).
In studies pooling low-grade astrocytomas and oligodendro-
gliomas, the IDH1 mutation status was prognostic for overall and 
PFS. In primary glioblastoma, IDH1 mutational status has been 
reported to be the only factor that showed significant association 
with patient survival times. However, the evidence for low-grade 
gliomas and the prognostic value of IDH1 mutation is slightly 
more controversial. Two independent groups found that IDH1 
mutations in low-grade gliomas were associated with significant 
improved overall survival (43, 44), whereas others could not find 
any significant association (36, 45). Nevertheless, the consistent 
finding of a more favorable outcome of diffuse gliomas patients 
with IDH1 mutation implies that IDH1 testing might be useful 
for prognostic considerations in the clinical setting.
Predictive implications
Isocitrate dehydrogenase 1 mutation was correlated with a higher 
rate of response to up-front temozolomide in low-grade glioma 
patients. Furthermore, evidence for differential responsiveness to 
genotoxic therapy of IDH1 mutant versus IDH1 wild-type low-
grade gliomas has been provided. Indeed, the presence of IDH1 
mutation was associated with favorable progression-free and 
overall survival in WHO grade II gliomas who received radio- or 
chemotherapy. Current studies aim to validate and clarify the 
predictive value of IDH1 mutation in the different glioma types.
It is still unclear if IDH1 mutational status is a prognostic 
indicator or predictive measure of response to treatment. 
Houillier and colleagues stratified a cohort of low-grade 
gliomas into three groups based on prognostic factors 
according to the presence of 1p19q deletion, IDH1 mutation, 
or both together (46). They found that each of these factors 
was an independent predictor of improved clinical outcome 
in response to treatment with the chemotherapeutic agent 
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temozolomide and that the group of patients with both muta-
tions had the best treatment response. Objective response was 
in 80% with both mutations, 61% of IDH1-mutants without 
1p19q deletion, and 17% without either mutation. In a similar 
fashion, Hartman and colleagues found that, in their cohort 
of patients receiving adjuvant therapy, IDH1 mutation status 
was the single most important predictor of PFS and overall 
survival. This was not seen in their cohort of patients that did 
not receive adjuvant therapy (47). These findings support the 
notion that IDH1 mutation may be an important predictor to 
treatment response.
Treatment implications
The identification of IDH1 mutation and the rapid characteriza-
tion of its protein products present a therapeutic opportunity 
to treat the IDH1-mutant tumors. From a medical standpoint, 
it will be important to determine whether these mutant tumors 
would be sensitive to molecules that inhibit the mutant enzyme. 
Although there are no published studies to date addressing this 
possibility, one study performed by Jin and colleagues suggested 
that mutant tumor cells may depend on the continued expression 
of the mutant enzyme and/or its resulting 2-HG metabolite. In 
their investigation, the authors showed that a cell line expressing 
endogenous mutant IDH1 required its expression for survival 
and anchorage-independent growth (48), suggesting that phar-
macological inhibition of mutant IDH1 may recapitulate this 
result. With respect to mutant IDH1-mediated biology, this result 
would also suggest that 2-HG-induced changes, such as global 
DNA hypermethylation, are either potentially reversible or, if 
not, are insufficient for tumor maintenance. It may be anticipated 
that inhibition of this pathway would increase patient survival. 
Although there has been some discussion of whether it is prudent 
to inhibit mutant IDH1 because patients with mutant tumors have 
a better survival than patients with wild-type tumors, it is not 
expected that inhibiting the mutant enzyme would make mutant 
tumors behave like their more aggressive wild-type counterparts. 
The differences in survival most likely stem from the fact that 
IDH1-mutant and wild-type tumors arise from distinct lineages 
and ontogenies and, thus, represent entirely different neoplastic 
disease processes.
ePiGeNeTiC CHANGeS iN 
GLiOBLASTOMA
Epigenetic is the mitotically heritable changes in gene expression 
that are not due to changes in the DNA sequence, and has emerged 
as hallmark of human cancers. Indeed, aberrant epigenetic 
mechanisms, such as DNA methylation, histone modifications, 
chromatin remodeling, or altered non-coding RNA expression, 
are currently recognized as relevant events in tumor formation 
(49). Until now, most studies about the epigenetic changes in glio-
blastoma have focused on DNA methylation, including hyper-
methylation, gene-specific hypomethylation, and genome-wide 
hypomethylation (50). The leading mechanism attributed to the 
observed hypermethylation phenotype in IDH1 mutant involves 
silencing of the α-KG-dependent DNA modifying enzyme, Tet 
methylcytosine dioxygenase 2 (TET2) (Figure 1).
Since the first report demonstrating that a subset of glioblas-
toma exhibits a global decrease in 5-methylcytosine, subsequent 
follow-up studies have revealed not only that genome-wide or 
global hypomethylation occurs at a frequency of 80% in primary 
glioblastoma, but also that the level of hypomethylation varies 
between glioblastomas, ranging from near normal levels to 
approximately 50% of normal in about 20% of cases (51). The 
most severe globally hypomethylated primary glioblastomas are 
also the most proliferative and display dramatic hypomethyla-
tion (22–50% of normal brain) of the tandem repeat satellite 2 
(Sat2) located at the juxtacentromeric region of chromosomes 1, 
9, and 16, and moderate hypomethylation (71–80%) of the D4Z4 
located at the subtelomeric regions of chromosomes 4q35 and 
10q26 (51). Moreover, glioblastoma with hypomethylated Sat2 
also harbored copy number alterations of adjacent euchromatic 
sequences, specifically near the pericentromeric region of chro-
mosome 1. These data suggest that one consequence of hypo-
methylated repetitive sequences in glioblastoma is predisposition 
to chromosomal breakage and copy number alteration. Although 
the full consequences of genomic hypomethylation are unknown, 
murine models of defective imprinting provide evidence for a 
causal role of DNA methylation alteration in tumorigenesis.
DNA methylation has been shown to play critical roles in the 
control of gene activity and the architecture of the nucleus of the 
cell. In humans, DNA methylation occurs in cytosines that pre-
cede the guanines to create 5-methylcytosine and these are com-
monly called dinucleotide CpGs (52). These dinucleotides are not 
randomly distributed in the genome, but instead are present as 
CpG-rich regions referred to as CpG islands. Hypermethylation of 
CpG islands in the promoter regions of tumor-suppressor genes is 
a major event in the origin of many cancers. In glioblastoma, CpG 
promoter hypermethylation occurs at genes with diverse func-
tions related to tumorigenesis and tumor progression, including 
cell cycle regulation (CDK2A-p16INK4a and CDK2B-p15INK4b) 
tumor suppression (RB1, VHL, EMP3, RASSF1A, and BLU), DNA 
repair [methylguanine DNA methyltransferase (MGMT) and 
MLH1], inhibition of apoptosis (DAPK1, TIMP3, CDH1), and 
genes associated with angiogenesis, regulation of tumor invasion, 
and drug resistance (53). Many new tumor-suppressor candidates 
have been identified, including the cell motility regulator testis-
derived transcript (TES) as well as many polycomb repressor 
complex 2 (PRC2) target genes (54), and epithelial membrane 
protein 3 (EMP3), a myelin-related gene involved in cell prolifera-
tion and cell–cell interaction that is silenced by hypermethylation 
in glioblastoma (55).
Promoter hypermethylation has been demonstrated to regu-
late the oncogenic and proliferation-promoting transforming 
growth factor (TGF)-beta signaling pathway in aggressive, highly 
proliferative glioblastomas. High levels of TGF-beta signaling are 
normally associated with poor prognosis. TGF-beta signaling 
promotes proliferation through the induction of platelet-derived 
growth factor-beta (PDGF-B). However, epigenetic silencing of 
PDGF-B can override the increased proliferative effects of TGF-
beta signaling. Specifically, PDGF-B promoter hypermethylation 
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prevents PDGF-B transcriptional activation by TGF-beta-induced 
Smad proteins (56). The oncogenic effect of the TGF-beta pathway 
is, therefore, blocked by epigenetic alteration of one of its targets.
Genes involved in invasion and metastasis can also be affected 
by promoter hypermethylation in glioblastoma. Approximately 
87% of glioblastoma exhibit CpG hypermethylation of the 
protocadherin-gamma subfamily A11 (PCDH-gamma-A11) 
gene, which is thought to be important in invasion of cancer cells 
into normal brain parenchyma (57).
The hypermethylation of promoter can also modulate sensitiv-
ity to drugs and radiotherapy in glioblastoma. The best known 
example is the O6-MGMT promoter methylation and response to 
alkylating agents, but there is also the gene suppressor of cytokine 
signaling 1 (SOCS1), which in some glioblastomas enhanced 
resistance to ionizing radiation and decreased activation of 
MAPKs associated with the ERK pathway after transcriptional 
silencing by hypermethylation (58). This suggests that epigenetic 
profiling might be one way to categorize glioblastomas and to 
rationally apply patient-specific therapy.
For certain sets of genes, promoter hypermethylation might not 
be causal or may not be required for gene silencing in glioblastoma. 
There is some evidence for deregulation of gene controlling histone 
modifications in this tumor. The gene encoding BMI-1, a member 
of the polycomb group complex that regulates histone H3K27 
methylation, is subject to frequent copy number alterations in both 
low- and high-grade gliomas (59). Expression of some histone dea-
cetylase (HDAC) proteins is reported to be altered in glioblastoma. 
Class II and IV HDACs displayed decreased mRNA expression 
in glioblastoma compared to low-grade astrocytomas and normal 
brain, and overall histone H3 was more acetylated in glioblastoma 
(60). Large-scale sequencing of protein-coding genes in glioblas-
toma revealed mutations in many genes involved in epigenetic 
regulation, including HDACs, HDAC2 and HDAC9, histone dem-
ethylases, JMD1A and JMD1B, histone methyltransferases, SET7, 
SETD7, MLL, MLL4, and methyl-CpG binding domain protein1 
(MBD1) (6). These intriguing initial studies suggest that alteration 
in epigenetic mechanisms could be a major defect in glioblastoma.
CONCLUSiON
Following the discovery of IDH1 mutation, our understanding of 
the biochemistry, genetics, and epigenetics as well as the preva-
lence and pathogenic role of this mutation has grown at a rapid 
rate, and a tremendous amount of work has been performed on 
its translational relevance in a relative short time. It is, henceforth, 
clear that IDH1 status is a major determinant of survival, and 
many ways have been developed to identify the IDH mutation 
as well as the oncometabolite 2-HG from clinical samples, using 
non-invasive procedures. The determination of IDH1 status in 
glioblastoma will likely be an early step in treatment algorithms 
for patients suffering from this tumor.
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